SABCS 2020 | PENELOPE-B: palbociclib with endocrine therapy in HR+, HER2-negative breast cancer

Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany, discusses the results of the Phase III PENELOPE-B study (NCT01864746), evaluating palbociclib combined with endocrine therapy in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancer and with high relapse risk after neoadjuvant chemotherapy. In this study, there was no significant difference between the two different treatment arms and Prof. Loibl explores why this may be the case including the fact that it was a high-risk population that was enrolled in this study. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).